Texas Semaglutide Laws & Insurance Dallas-Fort Worth: GLP-1 Coverage Guide 2026

Texas Medical Board Requirements for Semaglutide Prescribing

Texas regulates semaglutide prescribing through the Texas Medical Board (TMB), the Texas Board of Nursing (TBN), and the Texas Physician Assistant Board (TPAB). The rules governing who can prescribe, under what conditions, and how have direct practical consequences for DFW patients seeking GLP-1 medications as of March 2026 [1].

Physician Prescribing

Licensed physicians (MDs and DOs) in Texas may prescribe semaglutide autonomously, including via telehealth, without any additional certification or registration beyond their standard Texas medical license. The TMB requires that a valid patient-physician relationship be established before prescribing — which means either a prior in-person evaluation or a synchronous real-time audio-video telehealth visit. A phone call or asynchronous message exchange is insufficient to establish a new patient relationship under Texas standards [2].

Physicians must document clinical appropriateness in the patient record: BMI, relevant comorbidities, and a clinical justification for semaglutide over less costly alternatives. TMB Rule 190.8 requires prescriptions to be issued only after proper evaluation and based on medical necessity. Prescribers who issue semaglutide prescriptions without adequate evaluation risk disciplinary action from the TMB, a pattern the board has flagged in its 2025 enforcement guidance targeting telehealth-only weight loss services [2].

Nurse Practitioner (NP) Prescribing

Advanced Practice Registered Nurses (APRNs) in Texas may prescribe semaglutide under a Prescriptive Authority Agreement (PAA) with a delegating or supervising physician. A PAA is a formal written agreement that defines the scope of prescriptive authority the physician grants to the NP. Semaglutide is not a controlled substance, which simplifies NP prescribing considerably — NPs with a PAA may prescribe it without additional authorization beyond the standard agreement [1].

Texas Senate Bill 406 (2021) created a path to independent NP practice: APRNs with at least four years of full-time practice experience and 4,000 clinical hours may apply to the TBN for authority to practice and prescribe independently, without a PAA. Several DFW weight-loss clinics are staffed by independent NPs operating under this provision. Verify that your NP provider either has a PAA or meets the independent practice threshold — some DFW medspa operations have had their prescriptions challenged by pharmacies when PAA documentation was incomplete [1][2].

Physician Assistant (PA) Prescribing

Texas physician assistants (PAs) may prescribe non-controlled substances under a written delegation agreement from a supervising physician, per Texas Occupations Code Chapter 204. Semaglutide is not a controlled substance, so PAs can prescribe it when the delegation agreement specifically includes this drug category or a broad non-controlled drug authority. However, PAs cannot autonomously prescribe Schedule III-V controlled substances — meaning if a DFW clinic adds phentermine (Schedule IV) to a patient's weight-loss regimen, the PA must have explicit, separate physician delegation for that prescription [1].

Consultation Requirements

There is no Texas law mandating a specific minimum consultation time before prescribing semaglutide. The TMB requires a good-faith evaluation sufficient to establish a diagnosis and document medical necessity. In practice, DFW clinics use initial consultations of 20 to 60 minutes, often including a medical history review, BMI calculation, blood pressure measurement, and discussion of contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis, and severe gastrointestinal disease). This is a minimum clinical floor, not a legal mandate — but clinics that skip it face both TMB liability and malpractice exposure [2].

Insurance Coverage for Semaglutide by Texas Carrier

Five major carriers dominate the Dallas-Fort Worth commercial insurance market: Blue Cross Blue Shield of Texas, UnitedHealthcare, Aetna, Cigna, and Molina Healthcare. GLP-1 coverage varies substantially between plan types (employer-sponsored vs. ACA Marketplace vs. Medicaid) and between individual employer groups within the same carrier [3][4][5].

The table below summarizes the current landscape as of March 2026. This is not a guarantee of your specific plan — always call your carrier's pharmacy benefits line and ask specifically about Wegovy (NDC 00169-4922-12) coverage for the obesity indication before assuming anything [3].

Coverage as of March 2026. Employer plan coverage depends on your specific employer's benefit design — your employer may have carved out anti-obesity medications even if the carrier generally covers them. Source: SemaVerified carrier research [3][4][5].

Blue Cross Blue Shield of Texas

BCBS Texas is the largest commercial insurer in the DFW market and currently offers the most accessible path to branded Wegovy coverage. Under most employer-sponsored PPO and HMO plans, BCBS Texas covers Wegovy on Tier 5 (specialty drug) with prior authorization. BMI criteria follow the FDA label: BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea). BCBS Texas typically does not require step therapy — patients do not need to fail a cheaper weight-loss drug first [3].

The critical limitation: BCBS Marketplace (ACA) plans sold through healthcare.gov do not cover Wegovy for the obesity indication in Texas. Patients on BCBS Blue Advantage or Blue Choice ACA plans should not assume coverage. For Ozempic prescribed for type 2 diabetes (not weight loss), BCBS typically covers it on Tier 3 with a $35–75 copay [3].

UnitedHealthcare

UHC covers Wegovy on most employer plans in DFW, but requires step therapy on select employer group contracts. Step therapy means you must try and fail at least one alternative weight-management medication (typically phentermine or topiramate, both Schedule IV) before UHC will approve Wegovy. This adds 1–3 months to the process and creates a real barrier, particularly for patients with contraindications to stimulants. Ask your UHC benefits representative specifically: "Does my plan require step therapy for Wegovy?" before starting any prior authorization. UHC also requires a letter of medical necessity from the prescriber, which is not uniformly required by other carriers [4].

UHC's 2026 Medicare Advantage plans (offered through AARP-branded products in DFW) now cover Wegovy on select plans with prior authorization — a meaningful change from prior years when Medicare Part D prohibited anti-obesity drug coverage. However, not all UHC MA plans in DFW include this benefit; check your specific plan's Evidence of Coverage document [4].

Aetna

Aetna offers relatively straightforward prior authorization criteria for Wegovy on employer-sponsored plans: BMI 30+ or BMI 27+ with comorbidity, without a step therapy requirement. Aetna's PA approval timeline of 7–10 business days is mid-range among DFW carriers. Typical specialty copay is $25–125/month depending on the plan tier. Aetna Marketplace plans in Texas do not cover weight-loss GLP-1 medications [5].

Cigna

Cigna is the most restrictive major carrier for GLP-1 coverage in DFW. Many Cigna employer group plans have explicitly excluded anti-obesity medications from their formularies due to cost. When coverage is available, prior authorization can take up to 15 business days — the longest among the five carriers. Cigna Marketplace and individual plans in Texas do not cover Wegovy. If your employer uses Cigna, verify directly with Cigna's pharmacy benefits team (not general customer service) and ask for the specific formulary document for your group plan number [5].

Molina Healthcare

Molina is Texas's largest Medicaid managed care organization, covering approximately 2.3 million Texans in the Dallas and Tarrant County service areas. Molina Texas covers Ozempic only for the type 2 diabetes indication — never for weight loss. Medicaid patients in Texas have essentially no coverage for GLP-1 weight loss, regardless of BMI or comorbidities. This is a policy decision at the Texas Health and Human Services Commission level, not a Molina-specific decision [6].

Prior Authorization Process for Wegovy in DFW

Prior authorization (PA) for branded Wegovy is required by every major Texas commercial carrier. The process adds 5–15 business days between your prescription and coverage approval, and roughly 30–40% of initial submissions are denied. Here is exactly what happens, what you need, and how to appeal [3][4][5][7].

Step-by-Step Prior Authorization Process

Step 1: Initial clinical visit. Your DFW provider (physician, NP under PAA, or qualifying PA) evaluates you in person or via synchronous telehealth. They document your BMI, relevant comorbidities, and clinical rationale for semaglutide. This visit generates the medical records that support the PA request.

Step 2: Prescription submission. Your provider sends a Wegovy prescription to your preferred pharmacy (CVS, Walgreens, or a specialty pharmacy like Accredo or Optum Specialty). The pharmacy attempts to process the claim against your insurance.

Step 3: Insurance PA request triggered. Your insurer's pharmacy benefit manager (PBM) — CVS Caremark (BCBS TX), OptumRx (UHC), or CVS Caremark/Express Scripts (Aetna/Cigna) — flags the claim as requiring prior authorization and sends a PA request to your provider's office.

Step 4: Provider completes PA documentation. Your provider submits clinical documentation including: current BMI measurement (dated within 6 months), documentation of weight-related comorbidities, evidence of prior diet and exercise efforts (typically 3–6 months documented in chart notes), and a letter of medical necessity for UHC and some Cigna plans. Most DFW clinics manage this process for patients, but some require you to follow up proactively.

Step 5: Carrier review and decision. Timeline varies: BCBS Texas and UHC approve or deny within 5–10 business days; Aetna within 7–10; Cigna up to 15. Urgent PA requests (for patients with documented urgent medical need) must be resolved within 72 hours under Texas Department of Insurance rules [7].

Step 6: Approval or denial. If approved, you receive a PA authorization number valid for 12 months (at most carriers), renewable annually. If denied, you receive a written denial notice that must state the specific reason for denial and your appeal rights. Keep this document — you need it for the appeal.

Appeal Process

Approximately 40% of initial GLP-1 prior authorization denials are overturned on first appeal according to 2025 pharmacy benefit manager data [7]. The appeal process in Texas follows the Texas Department of Insurance (TDI) framework: your insurer must acknowledge a written appeal within 5 business days and resolve it within 30 calendar days for standard appeals, or 72 hours for expedited appeals when your health condition is urgent [7].

To strengthen your appeal: include a detailed physician letter addressing the specific denial reason, new documentation of comorbidities not in the original submission, and any peer-reviewed literature supporting semaglutide's clinical appropriateness for your profile. If your internal appeal is denied, Texas law entitles you to an independent review through TDI's Independent Review Organization (IRO) process, administered by an external medical reviewer. IRO decisions are binding on the insurer. Contact TDI at 1-800-252-3439 or tdi.texas.gov to initiate an independent review request [7].

Required documentation for a successful PA submission (March 2026):

• Current BMI with measurement date (within 6 months)
• Diagnosis code: E66.01 (morbid obesity due to excess calories) or E66.09 (other obesity)
• Documentation of at least one weight-related comorbidity if BMI is 27–29.9
• Chart notes or provider attestation of 3+ months of supervised diet and exercise attempts
• Letter of medical necessity (required by UHC; recommended for all carriers)
• Formulary exception letter if Wegovy is not on your plan's formulary

Medicare & Medicaid Coverage for GLP-1 in Texas

The coverage picture for DFW patients on Medicare or Texas Medicaid is largely negative as of March 2026, with one limited exception for Medicare Advantage plans [4][6][8].

Medicare Part D

Traditional Medicare Part D plans are prohibited by federal statute (Social Security Act Section 1860D-2(e)(2)) from covering drugs used "for weight loss purposes," which historically excluded GLP-1 receptor agonists prescribed for obesity. This prohibition has been in place since Part D's inception in 2006. Wegovy, approved by the FDA in 2021 specifically for chronic weight management, falls squarely under this exclusion for traditional Part D beneficiaries [8].

The only current exception: in 2024, the FDA approved Wegovy for reduction of cardiovascular risk in obese or overweight adults with established cardiovascular disease (heart attack, stroke, or heart failure). CMS issued guidance that Part D plans may cover Wegovy when prescribed for the cardiovascular risk indication (not the weight-loss indication) under this new labeling. However, coverage is not mandatory — each Part D plan decides whether to include it on their formulary. In DFW, check your specific Part D plan's 2026 formulary for Wegovy under the cardiovascular indication [8].

Medicare Advantage

Medicare Advantage (Part C) plans have more flexibility than traditional Medicare. As noted above, UnitedHealthcare Medicare Advantage plans in DFW now offer Wegovy coverage on select plans under prior authorization. Several Humana and Aetna Medicare Advantage plans in the Dallas market have also added GLP-1 coverage for the cardiovascular indication in 2026. If you are on a Medicare Advantage plan, review your plan's Evidence of Coverage document or call your plan's pharmacy benefits line to ask specifically about Wegovy coverage for your diagnosis [4].

Texas Medicaid

Medicaid patients in Texas have essentially no coverage for GLP-1 weight loss, full stop. The Texas Medicaid Vendor Drug Program (VDP) Preferred Drug List, updated March 2026, covers semaglutide (Ozempic) only for the type 2 diabetes indication, with prior authorization required [6]. Wegovy (the weight-management formulation) is not on the Texas Medicaid PDL for any indication. There is no exception for severe obesity, comorbidities, or other clinical circumstances.

The Texas Legislature considered two bills in the 2025 session that would have expanded Medicaid GLP-1 coverage — HB 1872 and SB 994 — neither advanced out of committee. Advocacy from the Obesity Medicine Association and Texas Medical Association continues, and the issue is expected to return in the 2027 legislative session. Until legislation passes, the approximately 4.2 million Texans enrolled in Medicaid who need GLP-1 treatment for weight loss must pay out-of-pocket or go without [6].

CHIP (Children's Health Insurance Program) in Texas similarly does not cover GLP-1 medications for weight management in pediatric patients, despite FDA approval of Wegovy for patients aged 12 and older in 2022 [6].

Telehealth Rules for GLP-1 Prescribing in Texas

Texas has one of the more permissive telehealth frameworks for non-controlled substance prescribing, which directly benefits DFW patients seeking semaglutide from out-of-area or virtual providers as of March 2026 [1][9].

Texas Telehealth Framework

Texas Occupations Code Chapter 111 governs telemedicine in the state. Key requirements for telehealth prescribing of semaglutide: the provider must be licensed in Texas; the encounter must use a synchronous real-time audio-video connection (not phone-only or asynchronous messaging) for establishing a new patient-provider relationship; and the provider must maintain a medical record documenting the evaluation and prescribing rationale [1].

Critically, Texas eliminated its "1-800 prescribing" prohibition in 2017 (SB 1107) — the law that previously required an in-person visit before any prescription could be issued. Today, a Texas-licensed provider can establish a new patient relationship and prescribe semaglutide entirely via telehealth as long as the encounter uses audio-video. This makes Texas more accessible for telehealth-first weight-loss services than states like Louisiana or Arkansas, which retained in-person visit requirements for controlled substances [9].

Federal Ryan Haight Act Considerations

The Ryan Haight Online Pharmacy Consumer Protection Act (2008) imposed federal restrictions on prescribing controlled substances via the internet without a prior in-person evaluation. Semaglutide is not a controlled substance under the DEA Controlled Substances Act, so the Ryan Haight Act does not apply to semaglutide prescribing. This is an important distinction: telehealth prescribing of semaglutide faces no Ryan Haight constraint, whereas prescribing phentermine (Schedule IV) or other controlled-substance weight-loss drugs via telehealth requires either a prior in-person visit or qualification under a narrow DEA telemedicine exception [9].

The DEA's 2025 telemedicine flexibilities — extended from the COVID-era public health emergency — continue to permit telehealth prescribing of some Schedule III-V controlled substances under specific conditions, but these extensions are subject to ongoing DEA rulemaking. DFW patients combining semaglutide with a controlled-substance adjunct should confirm their provider's compliance with current DEA telehealth rules [9].

DFW Clinics Offering Telehealth Semaglutide

Several DFW-based clinics offer synchronous telehealth consultations and can ship compounded semaglutide to Texas patients via partner pharmacies. InjectCo (Knox-Henderson, Dallas) advertises free virtual consultations for new patients, with medication shipped to your door from their compounding pharmacy partner. Vital Wellness Texas offers telehealth follow-up visits for established patients across both their Dallas and Frisco locations. Q Day Walk-In Clinic in Plano uses a hybrid model: in-person for the initial visit, telehealth for follow-ups [10].

Telehealth-only national platforms (Hims, Ro, Found, Henry Meds) are legally permitted to prescribe semaglutide to Texas patients under the Chapter 111 framework, provided they use Texas-licensed providers and synchronous video. However, these platforms exclusively prescribe compounded semaglutide, not branded Wegovy — meaning insurance coverage is unavailable regardless of your plan. If insurance coverage is a goal, a DFW clinic with in-person access and insurance billing capability is your better path [10].

Compounding Pharmacy Regulations for Semaglutide in Texas

The majority of DFW weight-loss clinics prescribe compounded semaglutide rather than branded Wegovy. Understanding the regulatory framework governing these pharmacies is essential for evaluating quality and legal risk [11][12].

503A vs. 503B Facilities

Federal law distinguishes two categories of compounding pharmacy. 503A pharmacies are traditional compounding pharmacies that produce medications for individual patients in response to a valid prescription. They are primarily regulated by state pharmacy boards (in Texas, the Texas State Board of Pharmacy, or TSBP) and must comply with USP Chapter 797 sterile compounding standards. 503A facilities can compound semaglutide for individual patients during the FDA shortage period, but cannot produce large batches for resale or general distribution [11].

503B outsourcing facilities are registered with the FDA and held to higher standards, including current Good Manufacturing Practice (cGMP) requirements typically applied to drug manufacturers. 503B facilities can produce larger quantities of compounded medications without patient-specific prescriptions and may ship directly to healthcare providers (rather than just to individual patients). The major 503B compounders serving DFW clinics include Empower Pharmacy (Houston, Texas) and Hallandale Compounding (Florida). Empower Pharmacy is a PCAB-accredited, FDA-registered 503B facility, which is the highest quality designation available for a compounding pharmacy [11].

Texas State Board of Pharmacy Oversight

The TSBP regulates both 503A and 503B compounding pharmacies operating in Texas under 22 TAC Chapter 291, Subchapter H (Pharmacies Compounding Sterile Preparations). Texas requirements include: licensed pharmacist-in-charge, written policies and procedures for sterile compounding, ongoing quality assurance testing, and physical facilities meeting USP 797 cleanroom standards [12].

TSBP conducts routine inspections of Texas-based compounding pharmacies, with specific attention to sterile injectable compounds like semaglutide. Violations identified in 2024 TSBP inspection reports for Texas compounding pharmacies included: improper storage of active pharmaceutical ingredients, inadequate potency testing, and failure to maintain cleanroom certification. Patients should ask their DFW clinic specifically: which compounding pharmacy supplies their semaglutide, whether that pharmacy is a 503A or 503B facility, and when the pharmacy's most recent state inspection occurred [12].

FDA Shortage Exemption and Its Limits

The legal basis for compounded semaglutide is Section 503B of the Federal Food, Drug, and Cosmetic Act, which permits compounding of drugs on the FDA's drug shortage list. Semaglutide has been on the shortage list since 2022 due to unprecedented demand for Wegovy and Ozempic. The FDA updated the shortage status as of March 2026 — semaglutide remains on the list, but the FDA has published notice that it is evaluating whether the shortage has been resolved for specific product strengths [11].

When the FDA removes semaglutide from the shortage list, 503B outsourcing facilities will no longer be permitted to produce copies of Wegovy. 503A pharmacies may retain limited ability to compound for individual patients under the "clinical difference" standard (demonstrating the patient needs a custom formulation not available commercially) — but this path is narrow and legally uncertain. DFW patients currently using compounded semaglutide at $249–400/month should have a contingency plan: either transition to branded Wegovy if they have qualifying insurance, or investigate other FDA-approved weight-management medications if semaglutide becomes unavailable as a compounded option [11][12].

Salt form issue: A 2024 FDA investigation found that some compounded semaglutide products used semaglutide sodium or acetate salts rather than the base form used in Wegovy. These salt forms have not been demonstrated to be bioequivalent to base semaglutide in the peer-reviewed literature. Ask your clinic whether their compounding pharmacy uses semaglutide base (matching Wegovy's active ingredient) or a salt form. This is a legitimate clinical question any reputable clinic should be able to answer [11].

Texas Semaglutide Regulations FAQ